ID   SNU-283
AC   CVCL_5044
SY   SNU283; NCI-SNU-283
DR   ArrayExpress; E-MTAB-3610
DR   CCLE; SNU283_LARGE_INTESTINE
DR   Cell_Model_Passport; SIDM00215
DR   ColonAtlas; SNU283
DR   Cosmic; 738862
DR   Cosmic; 2302008
DR   Cosmic; 2612376
DR   Cosmic; 2651853
DR   Cosmic-CLP; 1659929
DR   GEO; GSM887619
DR   GEO; GSM888703
DR   GEO; GSM1346854
DR   GEO; GSM1448123
DR   GEO; GSM1670466
DR   KCLB; 00283
DR   Wikidata; Q54955161
RX   PubMed=10362137;
RX   PubMed=10674020;
RX   PubMed=19956504;
RX   PubMed=22460905;
RX   PubMed=24755471;
RX   PubMed=25926053;
RX   PubMed=27397505;
RX   PubMed=30894373;
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Part of: Seoul National University (SNU) cell line collection.
CC   Doubling time: 42 hours (PubMed=10362137).
CC   Microsatellite instability: Stable (MSS) (PubMed=10674020; PubMed=25926053; Sanger).
CC   Omics: Deep exome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=1.3%; Native American=0.52%; East Asian, North=60.74%; East Asian, South=36.27%; South Asian=0%; European, North=0%; European, South=1.16% (PubMed=30894373).
CC   Derived from metastatic site: Omentum.
ST   Source(s): Cosmic-CLP; KCLB; PubMed=25926053
ST   Amelogenin: X
ST   CSF1PO: 11,13
ST   D13S317: 8,11
ST   D16S539: 9,12
ST   D21S11: 29,30
ST   D3S1358: 15,18
ST   D5S818: 9
ST   D7S820: 11
ST   FGA: 23,25
ST   TH01: 7,9
ST   TPOX: 8,11
ST   vWA: 14,19
DI   NCIt; C9383; Rectal adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Female
AG   62Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 24-05-19; Version: 20
//
RX   PubMed=10362137; DOI=10.1002/(SICI)1097-0215(19990611)81:6<902::AID-IJC11>3.0.CO;2-T;
RA   Oh J.-H., Ku J.-L., Yoon K.-A., Kwon H.-J., Kim W.-H., Park H.-S.,
RA   Yeo K.-S., Song S.-Y., Chung J.-K., Park J.-G.;
RT   "Establishment and characterization of 12 human colorectal-carcinoma
RT   cell lines.";
RL   Int. J. Cancer 81:902-910(1999).
//
RX   PubMed=10674020; DOI=10.1016/S0959-8049(99)00206-3;
RA   Ku J.-L., Yoon K.-A., Kim D.-Y., Park J.-G.;
RT   "Mutations in hMSH6 alone are not sufficient to cause the
RT   microsatellite instability in colorectal cancer cell lines.";
RL   Eur. J. Cancer 35:1724-1729(1999).
//
RX   PubMed=19956504; DOI=10.4143/crt.2005.37.1.1;
RA   Ku J.-L., Park J.-G.;
RT   "Biology of SNU cell lines.";
RL   Cancer Res. Treat. 37:1-19(2005).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=24755471; DOI=10.1158/0008-5472.CAN-14-0013;
RA   Mouradov D., Sloggett C., Jorissen R.N., Love C.G., Li S.,
RA   Burgess A.W., Arango D., Strausberg R.L., Buchanan D., Wormald S.,
RA   O'Connor L., Wilding J.L., Bicknell D.C., Tomlinson I.P.M., Bodmer W.F.,
RA   Mariadason J.M., Sieber O.M.;
RT   "Colorectal cancer cell lines are representative models of the main
RT   molecular subtypes of primary cancer.";
RL   Cancer Res. 74:3238-3247(2014).
//
RX   PubMed=25926053; DOI=10.1038/ncomms8002;
RA   Medico E., Russo M., Picco G., Cancelliere C., Valtorta E., Corti G.,
RA   Buscarino M., Isella C., Lamba S., Martinoglio B., Veronese S.,
RA   Siena S., Sartore-Bianchi A., Beccuti M., Mottolese M.,
RA   Linnebacher M., Cordero F., Di Nicolantonio F., Bardelli A.;
RT   "The molecular landscape of colorectal cancer cell lines unveils
RT   clinically actionable kinase targets.";
RL   Nat. Commun. 6:7002-7002(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//